S&P 500
7,695.94
+29.34
+0.38%
Dow
53,316.54
+254.59
+0.48%
Nasdaq
26,396.67
+178.84
+0.68%
NYSE Composite
24,617.61
+122.06
+0.50%
Russell 2000
2,963.89
+10.73
+0.36%
VIX
15.10
-0.10
-0.66%
CVS · CVS HEALTH CORPORATION
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
CVS Health Corp (CVS)
NEW YORK STOCK EXCHANGE, INC.
Health Care
$96.26
-0.95
(-0.98%)
● Market open
DAY'S RANGE
$96.26
$95.70
$97.89
52-WEEK RANGE
$96.26
$69.51
$110.68
What's happening
- CVS is down 0.98% today, trading at $96.26. — Live quote
- Volume today (67,787) is well below its 3-month average of 8,108,549. (Finnhub fundamentals)
- Last quarter's EPS beat estimates: $2.58 actual vs. $1.87 estimated (+38.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 20
Hold 5
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (33 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CVS
+22.52%
vs S&P 500
+10.31%
1-YEAR RETURN
CVS
+32.61%
vs S&P 500
+13.75%
6-MONTH RETURN
CVS
+21.69%
3-MONTH RETURN
CVS
+8.64%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-08-05 (Q2 2026)
$2.58
Est. $1.87
BEAT +38.0%
2026-04-26 (Q1 2026)
$2.57
Est. $2.22
BEAT +15.8%
2026-01-26 (Q4 2025)
$1.09
Est. $1.00
BEAT +8.8%
2025-10-26 (Q3 2025)
$1.60
Est. $1.38
BEAT +15.7%
Valuation Measures & Ratios
Enterprise Value4$172.54B
Forward P/E513.16
PEG Ratio63.30
Price / Sales (TTM1)0.29
Price / Book71.66
EV4 / Revenue0.42
EV4 / EBITDA19.67
Profit Margin1.18%
Operating Margin2.11%
Return on Equity (ROE8)6.41%
Return on Assets (ROA9)1.93%
Avg Volume (3M)8,108,549
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $132.55B | $90.53B | $92.80B | $84.41B | $81.14B |
| P/E | 44.66 | 51.20 | -85.29 | 18.13 | 17.09 |
| Price/Sales | 0.32 | 0.23 | 0.24 | 0.22 | 0.22 |
| Price/Book | 1.66 | 1.17 | 1.27 | 1.09 | 1.05 |
| EV/Revenue | 0.30 | 0.20 | 0.22 | 0.19 | 0.19 |
| EV/EBITDA | 9.25 | 6.86 | 10.62 | — | — |
| ROE | 3.72% | 2.28% | -1.49% | 6.02% | 6.17% |
| ROA | 1.17% | 0.70% | -0.43% | 1.80% | 1.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short16,823,735
Change from Prior Settlement-9.92%
% of Float—
Days to Cover (Short Ratio)1.80
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 7.3% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +32.6%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 1.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-08-17; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CVS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $106.10B | $100.43B | $102.87B | $98.92B | $94.59B | $95.43B | $91.23B | $88.44B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $4.70B | $4.68B | -$3.21B | $2.38B | $3.37B | $832.0M | $3.04B | $2.27B |
| Net income | $2.98B | $2.94B | -$3.98B | $1.02B | $1.78B | $87.0M | $1.77B | $1.11B |
| EPS (diluted) | $2.31 | $2.30 | $-3.13 | $0.80 | $1.41 | $0.07 | $1.41 | $0.88 |
| EPS (basic) | $2.33 | $2.31 | $-3.13 | $0.81 | $1.41 | $0.07 | $1.41 | $0.88 |
| Operating margin | $4 | $5 | -$3 | $2 | $4 | $1 | $3 | $3 |
| Net margin | $3 | $3 | -$4 | $1 | $2 | $0 | $2 | $1 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B | $253.22B | $252.43B |
| Total liabilities | $173.87B | $175.34B | $178.16B | $182.22B | $180.79B | $178.47B | $177.49B | $177.32B |
| Stockholders' equity | $79.70B | $77.46B | $75.21B | $72.93B | $77.38B | $76.93B | $75.56B | $74.94B |
| Total current assets | $75.35B | $74.82B | $74.71B | $77.11B | $75.65B | $73.19B | $68.64B | $67.34B |
| Total current liabilities | $87.04B | $86.41B | $88.69B | $92.69B | $94.16B | $88.96B | $84.61B | $84.63B |
| Cash & equivalents | $11.33B | $9.54B | $8.45B | $9.10B | $11.79B | $10.08B | $8.59B | $6.88B |
| Marketable securities (current) | $2.63B | $2.26B | $2.15B | $2.13B | $2.39B | $2.58B | $2.41B | $2.81B |
| Accounts receivable | $40.31B | $40.99B | $39.78B | $43.86B | $40.65B | $39.62B | $36.47B | $36.18B |
| Inventory | $17.62B | $17.77B | $19.25B | $18.96B | $17.45B | $17.39B | $18.11B | $17.65B |
| Other current assets | $3.46B | $4.25B | $5.09B | $3.06B | $3.38B | $3.53B | $3.08B | $3.83B |
| Marketable securities (non-current) | $33.25B | $32.41B | $32.67B | $31.55B | $29.86B | $28.91B | $28.93B | $28.94B |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $85.48B | $85.48B | $85.48B | $85.48B | $91.20B | $91.20B | $91.27B | $91.27B |
| Intangible assets | $24.64B | $25.07B | $25.51B | $25.98B | $26.22B | $26.57B | $27.32B | $27.82B |
| Other non-current assets | $7.43B | $7.42B | $7.11B | $5.16B | $5.21B | $5.23B | $4.79B | $4.76B |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | $22.48B | $22.26B | $22.39B | $23.41B | $23.10B | $22.37B | $20.81B | $20.17B |
| Deferred revenue (current) | — | — | $62.0M | $58.0M | $61.0M | $65.0M | $144.0M | $174.0M |
| Short-term debt | — | — | $0 | $1.25B | — | — | $2.12B | $800.0M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $6.11B | $6.71B | $6.77B | $4.76B | $4.78B | $5.42B | $5.43B | $5.48B |
| Common stock & paid-in capital | $50.97B | $50.68B | $50.40B | $50.18B | $50.02B | $49.84B | $49.66B | $49.51B |
| Retained earnings | $65.40B | $63.28B | $61.20B | $59.11B | $63.94B | $63.77B | $62.84B | $62.04B |
| Accumulated other comprehensive income (loss) | $188.0M | $201.0M | $406.0M | $416.0M | $272.0M | $59.0M | -$120.0M | $209.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.34B | $4.25B | $3.39B | $796.0M | $1.90B | $4.56B | $1.86B | -$745.0M |
| Investing cash flow | -$1.88B | -$874.0M | -$2.00B | -$2.09B | -$1.02B | -$762.0M | -$547.0M | -$3.35B |
| Financing cash flow | -$2.69B | -$2.32B | -$2.03B | -$1.38B | $806.0M | -$2.33B | $431.0M | -$1.59B |
| Free cash flow | $5.65B | $3.40B | $2.61B | $98.0M | $1.29B | $3.81B | $1.09B | -$1.42B |
| Capital expenditures | $691.0M | $849.0M | $784.0M | $698.0M | $607.0M | $743.0M | $768.0M | $670.0M |
| Depreciation & amortization | $1.13B | $1.11B | $3.45B | $1.13B | $1.17B | $1.15B | $3.46B | $1.16B |
| Share-based compensation | $176.0M | $266.0M | $135.0M | $138.0M | $136.0M | $126.0M | $137.0M | $133.0M |
| Deferred income taxes | — | — | $102.0M | — | — | — | -$572.0M | — |
| Change in accounts receivable | -$672.0M | $1.21B | -$4.04B | $3.40B | $1.09B | $3.05B | $315.0M | $3.78B |
| Change in inventory | -$148.0M | -$1.48B | $285.0M | $1.65B | $51.0M | -$722.0M | $457.0M | $1.58B |
| Change in accounts payable | $218.0M | -$562.0M | -$1.20B | $1.22B | $1.21B | $2.62B | $166.0M | $978.0M |
| Purchases of investments | $4.52B | $4.19B | $3.97B | $3.86B | $3.63B | $3.55B | $2.51B | $5.90B |
| Sales/maturities of investments | $1.94B | $2.95B | $6.40B | $1.84B | $2.62B | $2.19B | $5.22B | $2.32B |
| Other investing activities | -$5.0M | -$7.0M | -$17.0M | $14.0M | -$4.0M | -$19.0M | -$26.0M | -$15.0M |
| Dividends paid | $878.0M | $847.0M | $845.0M | $846.0M | $866.0M | $840.0M | $838.0M | $837.0M |
| Share repurchases | — | — | $0 | $0 | $0 | $0 | $0 | -$1.0M |
| Debt issued | — | — | $0 | $3.97B | $0 | — | $2.95B | $0 |
| Debt repaid | $1.77B | $1.52B | $20.0M | $2.85B | $19.0M | $743.0M | $3.07B | $1.67B |
| Tax withholding on stock comp | $145.0M | $9.0M | $13.0M | $20.0M | $114.0M | $11.0M | $4.0M | $5.0M |
| Other financing activities | -$15.0M | -$47.0M | $7.0M | $38.0M | -$22.0M | -$23.0M | $48.0M | $8.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B |
| Gross profit | — | — | — | — | — |
| Operating income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B |
| EPS (diluted) | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 |
| EPS (basic) | $1.40 | $3.67 | $6.49 | $3.29 | $6.07 |
| Operating margin | $1 | $2 | $4 | $2 | $5 |
| Net margin | $0 | $1 | $2 | $1 | $3 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B |
| Stockholders' equity | $75.21B | $75.56B | $76.46B | $71.47B | $75.08B |
| Total current assets | $74.71B | $68.64B | $67.86B | $65.63B | $60.01B |
| Total current liabilities | $88.69B | $84.61B | $79.19B | $69.42B | $67.81B |
| Cash & equivalents | $8.45B | $8.59B | $8.20B | $12.95B | $9.41B |
| Marketable securities (current) | $2.15B | $2.41B | $3.26B | $2.78B | $3.12B |
| Accounts receivable | $39.78B | $36.47B | $35.23B | $27.28B | $24.43B |
| Inventory | $19.25B | $18.11B | $18.02B | $19.09B | $17.76B |
| Other current assets | $5.09B | $3.08B | $3.15B | $2.64B | $5.29B |
| Marketable securities (non-current) | $32.67B | $28.93B | $23.02B | $21.10B | $23.02B |
| Property, plant & equipment | — | — | — | $12.87B | $12.90B |
| Goodwill | $85.48B | $91.27B | $91.27B | $78.15B | $79.12B |
| Intangible assets | $25.51B | $27.32B | $29.23B | $24.80B | $29.03B |
| Other non-current assets | $5.12B | $4.79B | $4.66B | $4.62B | $4.71B |
| Accounts payable | — | — | — | — | — |
| Accrued liabilities | $22.39B | $20.81B | $23.52B | $18.75B | $17.67B |
| Deferred revenue (current) | $62.0M | $144.0M | $149.0M | $71.0M | $87.0M |
| Short-term debt | $0 | $2.12B | $200.0M | $0 | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | $4.78B | $5.43B | $6.21B | $6.73B | $1.90B |
| Common stock & paid-in capital | $50.40B | $49.66B | $48.99B | $48.19B | $47.38B |
| Retained earnings | $61.20B | $62.84B | $61.60B | $56.40B | $54.91B |
| Accumulated other comprehensive income (loss) | $406.0M | -$120.0M | -$297.0M | -$1.26B | $965.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B |
| Investing cash flow | -$5.87B | -$7.61B | -$20.89B | -$5.05B | -$5.26B |
| Financing cash flow | -$4.94B | -$1.14B | $2.68B | -$10.52B | -$11.36B |
| Free cash flow | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B |
| Capital expenditures | $2.83B | $2.78B | $3.03B | $2.73B | $2.52B |
| Depreciation & amortization | $4.61B | $4.60B | $4.37B | $4.22B | $4.49B |
| Share-based compensation | $535.0M | $540.0M | $588.0M | $447.0M | $484.0M |
| Deferred income taxes | $102.0M | -$572.0M | -$676.0M | -$2.03B | -$402.0M |
| Change in accounts receivable | $3.50B | $1.30B | $6.26B | $2.97B | $2.70B |
| Change in inventory | $1.27B | $102.0M | -$1.23B | $1.44B | -$735.0M |
| Change in accounts payable | $3.85B | $2.33B | $3.62B | $4.26B | $2.90B |
| Purchases of investments | $15.01B | $15.19B | $9.04B | $7.75B | $9.96B |
| Sales/maturities of investments | $8.59B | $6.49B | $5.03B | $4.24B | $3.57B |
| Other investing activities | -$26.0M | -$101.0M | -$68.0M | -$85.0M | -$122.0M |
| Dividends paid | $3.40B | $3.37B | $3.13B | $2.91B | $2.62B |
| Share repurchases | $0 | $3.02B | $2.01B | $3.50B | $0 |
| Debt issued | $3.97B | $7.91B | $10.90B | $0 | $987.0M |
| Debt repaid | $3.63B | $4.77B | $3.17B | $4.21B | $10.25B |
| Tax withholding on stock comp | $158.0M | $185.0M | $181.0M | $370.0M | $168.0M |
| Other financing activities | $0 | $26.0M | -$201.0M | -$79.0M | $155.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CVS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-31 to 2026-06-26
Recent transactions
- Insiders have net sold 3,441,551 shares over the last 182 days, across 0 purchases and 8 sales.
- Most recent: Clark James David (SVP, Cont & Chief Acct Officer) — Tax withholding of 454 shares on 2026-06-26.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)3,441,551 sh(8 txns)
Net Shares-3,441,551
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Clark James David | SVP, Cont & Chief Acct Officer | Tax withholding | 2026-06-26 | 454 |
| Newman Brian | EVP, Chief Financial Officer | Tax withholding | 2026-05-31 | 2,478 |
| Compton-Phillips Amy | EVP, Chief Medical Officer | Tax withholding | 2026-05-31 | 7,618 |
| AGUIRRE FERNANDO | Director | Disposition to issuer | 2026-05-21 | 1,563 |
| ROBBINS LARRY | Reporting person | Open market sale | 2026-05-21 | 370,462 |
| Balser Jeffrey R. | Director | Grant / award | 2026-05-14 | 2,058 |
| KIRBY J SCOTT | Director | Grant / award | 2026-05-14 | 1,447 |
| Norwalk Leslie V | Director | Grant / award | 2026-05-14 | 1,447 |
| SANSONE GUY P | Director | Grant / award | 2026-05-14 | 1,447 |
| BROWN C DAVID II | Director | Grant / award | 2026-05-14 | 1,544 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | Open market sale | 2026-05-08 | 69,551 |
| Shah Prem S | EVP and Group President | Tax withholding | 2026-04-01 | 1,484 |
| Nelson Steven H | EVP and President, Aetna | Tax withholding | 2026-04-01 | 2,432 |
| Khichi Samrat S. | EVP, CPO and General Counsel | Tax withholding | 2026-04-01 | 3,541 |
| Joyner J. David | President, CEO and Chair | Tax withholding | 2026-04-01 | 8,029 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-26 | Clark James David | SVP, Cont & Chief Acct Officer | Tax withholding | 454 | $90.98 |
| 2026-05-31 | Newman Brian | EVP, Chief Financial Officer | Tax withholding | 2,478 | $90.98 |
| 2026-05-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | Tax withholding | 7,618 | $90.98 |
| 2026-05-21 | AGUIRRE FERNANDO | Director | Disposition to issuer | 1,563 | $93.50 |
| 2026-05-21 | ROBBINS LARRY | Reporting person | Open market sale | 370,462 | $93.45 |
| 2026-05-20 | AGUIRRE FERNANDO | Director | Disposition to issuer | 30,437 | $93.78 |
| 2026-05-20 | ROBBINS LARRY | Reporting person | Open market sale | 797,628 | $93.48 |
| 2026-05-20 | ROBBINS LARRY | Reporting person | Open market sale | 152,691 | $94.81 |
| 2026-05-20 | ROBBINS LARRY | Reporting person | Open market sale | 66,881 | $95.67 |
| 2026-05-20 | ROBBINS LARRY | Reporting person | Open market sale | 800 | $96.28 |
| 2026-05-19 | ROBBINS LARRY | Reporting person | Open market sale | 1,983,387 | $94.45 |
| 2026-05-19 | ROBBINS LARRY | Reporting person | Open market sale | 151 | $95.18 |
| 2026-05-14 | AGUIRRE FERNANDO | Director | Grant / award | 1,563 | $97.15 |
| 2026-05-14 | Balser Jeffrey R. | Director | Grant / award | 2,058 | $97.15 |
| 2026-05-14 | KIRBY J SCOTT | Director | Grant / award | 1,447 | $97.15 |
| 2026-05-14 | Norwalk Leslie V | Director | Grant / award | 1,447 | $97.15 |
| 2026-05-14 | SANSONE GUY P | Director | Grant / award | 1,447 | $97.15 |
| 2026-05-14 | BROWN C DAVID II | Director | Grant / award | 1,544 | $97.15 |
| 2026-05-08 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Open market sale | 69,551 | $89.58 |
| 2026-04-01 | Shah Prem S | EVP and Group President | Tax withholding | 1,484 | $72.49 |
| 2026-04-01 | Nelson Steven H | EVP and President, Aetna | Tax withholding | 2,432 | $72.49 |
| 2026-04-01 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Tax withholding | 3,634 | $72.49 |
| 2026-04-01 | Khichi Samrat S. | EVP, CPO and General Counsel | Tax withholding | 3,541 | $72.49 |
| 2026-04-01 | Joyner J. David | President, CEO and Chair | Tax withholding | 8,029 | $72.49 |
| 2026-03-31 | Shah Prem S | EVP and Group President | Grant / award | 25,062 | $71.82 |
| 2026-03-31 | Newman Brian | EVP, Chief Financial Officer | Grant / award | 19,493 | $71.82 |
| 2026-03-31 | Nelson Steven H | EVP and President, Aetna | Grant / award | 22,277 | $71.82 |
| 2026-03-31 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Grant / award | 22,277 | $71.82 |
| 2026-03-31 | Khichi Samrat S. | EVP, CPO and General Counsel | Grant / award | 12,531 | $71.82 |
| 2026-03-31 | Joyner J. David | President, CEO and Chair | Grant / award | 86,326 | $71.82 |
| 2026-03-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | Grant / award | 5,569 | $71.82 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 14:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-17 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-05-31 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-05-31 | View on SEC.gov → |
| 2026-05-22 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-18 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-05-15 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-15 | 4 | 2026-05-14 | View on SEC.gov → |
| 2026-05-15 | 4 | 2026-05-14 | View on SEC.gov → |
Recent news
Headlines about CVS (CVS HEALTH CORPORATION). Links open the publisher — we don’t host full articles.
-
ExchangeRight Fully Subscribes $63.34 Million Net-Leased Portfolio 74 DST
Yahoo Finance · 2026-09-02 -
LOVB Announces CVS Pharmacy as an Official Health & Wellness Partner
Yahoo Finance · 2026-09-02 -
Here's How CVS' Improving Balance Sheet Supports Deleveraging
Yahoo Finance · 2026-09-02 -
MBody AI Orchestrator Named Finalist for AI Deployment of the Year
Yahoo Finance · 2026-09-02 -
CVS Health (CVS) Climbed Today, But What Is Catching The Market's Attention?
Yahoo Finance · 2026-09-02 -
25 Years After 9/11, Communities Nationwide Turn Remembrance into Action with Travis Manion Foundation's 9/11 Heroes Run
Yahoo Finance · 2026-09-01 -
Why CVS Stock Rallied Tuesday Morning
Yahoo Finance · 2026-09-01 -
200,000 Medicare users sprint to CVS and Walgreens to snatch up $50 obesity drugs — millions more are still missing out
Yahoo Finance · 2026-08-31
No headlines in this category right now — try “All”.